DFDA

Durvalumab + Gemcitabine/Cisplatin

Treatment for Gallbladder And Biliary Tract Cancer

Typical Dosage: Durvalumab 1500mg IV every 3 weeks (with GemCis for 8 cycles, then monotherapy)

Effectiveness
60%
Safety Score
28%
Clinical Trials
5
Participants
10K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
28
DangerousModerateSafe
Treatment Details
Dosage Range
Durvalumab 1500mg IV every 3 weeks (with GemCis for 8 cycles, then monotherapy)
Time to Effect
1-3 months
Treatment Duration
Until progression or unacceptable toxicity (6-18+ months)
Evidence Quality
HIGH
Number Needed to Treat (NNT)
12(Treat 12 patients to see 1 additional successful outcome)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$130,000
Monitoring:$20,000
Side Effect Mgmt:$15,000
Total Annual:$165,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POOR
ICER
$300,000/QALY
QALYs Gained
0.9
Outcome-Based Costs
Cost per Responder
$611,111
Cost per Remission
$5,500,000
Comparison vs Gemcitabine + Cisplatin
Cost Difference
+$120,000/year
More expensive
QALY Difference
+0.15 QALYs
Better outcomes
Dominance
No dominance
Durvalumab + Gemcitabine/Cisplatin Outcomes

for Gallbladder And Biliary Tract Cancer

Efficacy Outcomes
Overall Effectiveness
+60%
Response Rate
+27%
Remission Rate
+3%
Common Side Effects
Myelosuppression
+55%
Fatigue
+60%
Nausea/Vomiting
+40%
Peripheral neuropathy
+30%
Immune-related adverse events
+10%

Sources:

nih.gov
nih.gov
onclive.com

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
4 active trials recruiting for Durvalumab + Gemcitabine/Cisplatin in Gallbladder And Biliary Tract Cancer

A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

NCT07221253RECRUITINGPHASE3
View Study
1.1K participants
INTERVENTIONAL
Birmingham, United States +161 more
Started: Dec 4, 2025

Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer

NCT04308174ACTIVE NOT RECRUITINGPHASE2
View Study
45 participants
INTERVENTIONAL
Seoul, South Korea
Started: May 20, 2020

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

NCT06282575RECRUITINGPHASE3
View Study
286 participants
INTERVENTIONAL
Duarte, United States +182 more
Started: Jul 19, 2024

A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors

NCT05712356ACTIVE NOT RECRUITINGPHASE2
View Study
67 participants
INTERVENTIONAL
Gilbert, United States +18 more
Started: Aug 24, 2023
Completed Clinical Trials
1 completed trial for Durvalumab + Gemcitabine/Cisplatin in Gallbladder And Biliary Tract Cancer

Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients

NCT03473574COMPLETEDPHASE2
View Study
128 participants
INTERVENTIONAL
Hanover, Germany
Started: May 2, 2018